New Research Of Children's Autism

New Research Of Children's Autism.
An speculative drug for autism did not fix up levels of lethargy and social withdrawal in children who took it, but it did show some other benefits, a different study finds in May 2013. Children on arbaclofen did improve on an overall measure of autism bareness when compared to kids taking an inactive placebo, said lead researcher Dr Jeremy Veenstra-VanderWeele, an associated professor of psychiatry, pediatrics and pharmacology at Vanderbilt University. He is to present the findings Thursday at the International Meeting for Autism Research (IMFAR) in Spain.

One of 88 children in the United States is now diagnosed with an autism spectrum disorder, the cover period for complex brain enlargement disorders marked by problems in social interaction and communication. Veenstra-VanderWeele focused on evaluating the communal improvement with the drug because earlier research had suggested it could help. However, one of the earlier studies did not weigh the drug to a placebo, but simply measured improvement in those who took the drug.

In the new study, Veenstra-VanderWeele and his tandem assigned 150 people with autism, aged 5 to 21, to take the drug or a placebo, without knowing which group they were in, for eight weeks. The participants had been diagnosed with autistic disorder, Asperger's syndrome or another connected condition known as pervasive developmental disorder. In all, 130 finished the study.